Does a routine invasive strategy reduce the composite of death, MI, or stroke compared with a selective invasive strategy in women with non-ST-elevation acute coronary syndromes?
A routine invasive strategy does not appear to benefit women with non-ST-elevation acute coronary syndromes and may be associated with higher mortality and bleeding risks compared to a selective invasive strategy.
AIMS: The aim of this study was to compare benefits and risks of a routine invasive compared with a selective invasive strategy in women with non-ST-elevation acute coronary syndromes. METHODS AND RESULTS: We randomly assigned 184 women, either to a routine or to a selective invasive strategy as a substudy to the OASIS 5 trial, who were followed for 2 years. Meta-analysis of data from previous randomized trials was also done. There were no significant differences between the two treatment strategies in the primary outcome death/myocardial infarction (MI)/stroke 21.0 vs. 15.4%, HR = 1.46, 95% CI (0.73-2.94), in the secondary outcome death/MI 18.8 vs. 14.3%, HR = 1.39, 95% CI (0.67-2.88), or separately analysed outcomes MI 12.9 vs. 13.3%, HR = 0.95, 95% CI (0.42-2.19) or stroke 2.3 vs. 4.4%, HR = 0.67, 95% CI (0.12-3.70). However, there were significantly more deaths after 1 year (8.8 vs. 1.1%, HR = 9.01, 95% CI (1.11-72.90) and a higher rate of major bleeding at 30 days 8.8 vs. 1.1%, HR = 11.45, 95% CI (1.43-91.96) in the routine invasive strategy group. A meta-analysis including 2692 women in previous randomized trials, with a gender perspective, showed no significant difference in the composite outcome death/MI, OR = 1.18, 95% CI (0.92-1.53) but a higher mortality with a routine invasive strategy for women, OR = 1.51, 95% CI (1.00-2.29). CONCLUSION: The rate of death, MI, or stroke in women was not different in patients treated with a routine invasive strategy compared with a selective invasive strategy, but there was a concerning trend towards higher mortality. When combined with data from previous trials, there does not appear to be a benefit of an early invasive strategy in women with ACS, which differs from the results in men. These data emphasize the lack of clear evidence in favour of an invasive strategy in women and suggest caution in extrapolating the results from men to women.
Swahn et al. (Sat,) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: